FDA 483 OBSERVATION · #239 OF 1,945 MOST-CITED

Annual visual exams of drug products

FDA cited this observation 126 times across 122 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs126
BY FISCAL YEAR
FY20267
FY202514
FY20245
FY20236
FY202211
FY202110
FY20205
FY201917
FY201822
FY201715
FY201614

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.9× the rate of the average FDA-cited firm (30.3% vs 7.8%), across 122 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Conopco Inc. d/b/a Unilever · Raeford, North Carolina · Drugs · 2026-07-13

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Advagen Holdings, Inc. · East Brunswick, New Jersey · Drugs · 2026-05-13

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

KDC/ONE SOCAL LABORATORIES, LLC · Walnut, California · Drugs · 2026-04-14

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Deciem Inc. · Etobicoke · Drugs · 2026-04-02

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Gilead Sciences, Inc. · La Verne, California · Drugs · 2026-02-18

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Bavarian Nordic A/S · Kvistgard · Drugs · 2025-12-09

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →